HBP News and Press, Huttig Building Products Inc. From 04/30/19

Huttig Building Products ( HBP -5.4% ) reported net sales of $197.4M a slight decrease of 0.3% Y/Y, due to lower market activity and severe weather. More news on: Huttig Building Products, Inc., Earnings news and commentary, Stocks on the move, , Read more ...

RICHMOND HILL, Ontario, April 29, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it...

Huttig Building Products (NASDAQ: HBP ): Q1 GAAP EPS of -$0.13. Revenue of $197.4M (-0.3% Y/Y) Press Release More news on: Huttig Building Products, Inc., Earnings news and commentary, ,

First Quarter 2019 Highlights: Net sales of $197.4 million, impacted by lower market activity and severe weather Total cash used in operating activities decreased $34.4 million as compared to prior year Liquidity improved more than 17% to $53.0 million compared to $45.2 millio...

RICHMOND HILL, Ontario, April 18, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it...

RICHMOND HILL, Ontario, April 17, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it...

ST. LOUIS, Mo., April 16, 2019 (GLOBE NEWSWIRE) -- Huttig Building Products (Nasdaq: HBP), one of the nation's largest wholesale distributors of millwork and specialty building products used principally in new residential construction and home improvement, plans to release its first quarter...

RICHMOND HILL, Ontario, April 15, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced th...

RICHMOND HILL, Ontario, March 18, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP ) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, a...

RICHMOND HILL, Ontario, March 15, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has c...